Actively Recruiting
Phase 3 Study Comparing SCTB35 Plus Gemcitabine and Oxaliplatin to Rituximab Plus Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Led by Sinocelltech Ltd. · Updated on 2026-08-13
101
Participants Needed
1
Research Sites
73 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of SCTB35 combined with Gemcitabine and Oxaliplatin compared to Rituximab combined with Gemcitabine and Oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma. The study is a Phase 3 randomized trial designed to assess these treatments in adults aged 18 to 80 who have previously undergone therapy including an anti-CD20 monoclonal antibody and chemotherapy. Participants receive either SCTB35 by subcutaneous injection plus intravenous Gemcitabine and Oxaliplatin, or intravenous Rituximab with Gemcitabine and Oxaliplatin. These treatments are given for up to eight cycles. The study compares the two treatment combinations to evaluate their effects and safety. During the study, participants will be monitored for adverse events and progression-free survival for up to approximately three years. Other assessments include overall survival, response rates, duration of response, and blood levels of SCTB35. Safety and immune response markers will be tracked, with follow-up visits scheduled throughout the study duration to thoroughly evaluate treatment outcomes and participant health.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here